Survodutide heads to EASD without a filing date

Boehringer Ingelheim is heading into the European Association for the Study of Diabetes (EASD) Congress in Milan, running September 28 through October 2, without a published U.S. filing date or launch timeline for survodutide, its glucagon/GLP-1 dual agonist for obesity ^[2]. That is despite the company reporting in April 2026 that the drug produced up to 16.6% average weight loss at 76 weeks in its pivotal SYNCHRONIZE-1 obesity trial ^[1].

In SYNCHRONIZE-1, 725 adults with obesity or overweight who did not have type 2 diabetes received weekly injections of survodutide at 3.6 mg or 6.0 mg, or a placebo, over 76 weeks ^[1]. Participants on survodutide lost an average of up to 39.2 pounds (17.8 kg), or 16.6% of body weight, compared with 3.2% in the placebo group, a difference the company says was statistically significant (p<0.0001) ^[1]. About 85.1% of people on survodutide lost at least 5% of their body weight, versus 38.8% on placebo ^[1]. The trial also met a secondary goal of reducing waist circumference, a marker linked to visceral fat and cardiometabolic risk ^[1]. Boehringer said initial analysis suggests most of the weight loss came from fat rather than lean mass ^[1]. As with other GLP-1 class drugs, participants experienced gastrointestinal side effects, most often during the dose-escalation phase, described as mild to moderate and temporary, with no new safety signals beyond what is typical for the drug class ^[1].

Survodutide combines GLP-1 agonism, which reduces appetite and increases fullness, with glucagon agonism, which the company says acts on the liver to reduce fat buildup and inflammation ^[1]. That liver-focused mechanism is why the drug also holds FDA Breakthrough Therapy designation, granted in September 2024, for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis, plus Fast Track designation from May 2021 ^[1]. Two Phase 3 liver trials, called LIVERAGE and LIVERAGE-Cirrhosis, are underway, planning to enroll roughly 1,800 and 1,590 adults respectively, along with a separate cardiovascular outcomes trial (SYNCHRONIZE-CVOT) ^[1].

The next major data point is SYNCHRONIZE-2, a companion trial testing survodutide in people with obesity and type 2 diabetes. Results are expected to be presented at EASD on October 1 ^[2]. Other closely watched presentations that week include Phase 2 data on eloralintide combined with tirzepatide and Phase 2 trials of a compound called UBT251 ^[2]. Full detailed results from SYNCHRONIZE-1 itself were expected to be presented at the American Diabetes Association's Scientific Sessions in June 2026, according to Boehringer's April announcement ^[1].

Why it matters for patients

Survodutide is not approved anywhere and remains investigational, meaning its full safety and effectiveness profile has not been established through regulatory review ^[1]. For patients weighing current GLP-1 options like semaglutide or tirzepatide, the lack of a stated U.S. filing date means survodutide is not something to expect on pharmacy shelves in the near term. The sources reviewed here do not say when, or whether, Boehringer plans to submit an application to the FDA, so any timeline for approval or launch is not yet known.

The drug's dual mechanism, targeting both appetite and liver fat, is part of what generates interest, since it is being studied specifically in people with MASH and liver fibrosis in addition to obesity ^[1]. But that broader development program, spanning obesity, diabetes, liver disease, and cardiovascular outcomes, also means Boehringer may be waiting for more trial data before deciding on a regulatory path.

What happens next

SYNCHRONIZE-2 data in people with type 2 diabetes are expected to be presented at EASD on October 1, 2026 ^[2]. Boehringer's ongoing LIVERAGE, LIVERAGE-Cirrhosis, and SYNCHRONIZE-CVOT trials do not have publicly stated completion dates in the material reviewed here ^[1]. No U.S. filing or launch date has been announced ^[1][2].